Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure

Jonathan Paolino; Nancy Berliner; Barbara Degar

doi:10.3389/fonc.2022.1016318

Frontiers in Oncology (Oct 2022)

Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure

Jonathan Paolino,
Nancy Berliner,
Barbara Degar

Affiliations

Jonathan Paolino: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
Nancy Berliner: Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
Barbara Degar: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

DOI: https://doi.org/10.3389/fonc.2022.1016318
Journal volume & issue: Vol. 12

Abstract

Read online

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of multiorgan system dysfunction that is caused by hypercytokinemia and persistent activation of cytotoxic T lymphocytes and macrophages. A nearly ubiquitous finding and a diagnostic criterion of HLH is the presence of cytopenias in ≥ 2 cell lines. The mechanism of cytopenias in HLH is multifactorial but appears to be predominantly driven by suppression of hematopoiesis by pro-inflammatory cytokines and, to some extent, by consumptive hemophagocytosis. Recognition of cytopenias as a manifestation of HLH is an important consideration for patients with bone marrow failure of unclear etiology.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords